DUR Board Meeting Agenda

April 7th, 2015 6:00 – 8:30 p.m.

1. Executive Session 6:00 - 6:30

2. Introductions and Approval of DUR Board Minutes 6:30 - 6:40
   (Public Comment Prior to Board Action)

3. DVHA Pharmacy Administration Updates 6:40 - 6:50
   ▪ Updates

4. Medical Director Update 6:50 – 7:00
   ▪ Clinical Programs Update
   ▪ Prescriber Comments

5. Follow-up Items from Previous Meetings 7:00 - 7:00
   ▪ None at this time

6. RetroDUR/DUR 7:00 – 7:20
   ▪ High dose/Long term use in individual patients on diazepam
   ▪ Amiodarone DDI

7. Clinical Update: Drug Reviews 7:20 – 7:30
   (Public comment prior to Board action)
   Abbreviated New Drug Reviews
   ▪ None at this time

   Full New Drug Reviews
   ▪ Bunavair® (buprenorphine HCl & naloxone HCl dihydrate)
   ▪ Zubsolv® (buprenorphine & naloxone)

8. Therapeutic Drug Classes – Periodic Review 7:30 – 8:00
   (Public comment prior to Board action)
   ▪ Anti-migraines
   ▪ Antivirals, Topical
   ▪ GI Ulcer Therapies
   ▪ Fibromyalgia Agents
   ▪ Leukotriene Modifiers
   ▪ Gaucher Disease

9. New Managed Therapeutic Drug Classes 8:00 – 8:00
   (Public comment prior to Board action)
   ▪ None at this time

10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products 8:00 – 8:00
    (Public comment prior to Board action)
Selected FDA Safety Alerts

FDA Drug Safety Communication: FDA requires label warnings to prohibit sharing of multi-dose diabetes pen devices among patients


Testosterone Products: Drug Safety Communication - FDA Cautions About Using Testosterone Products for Low Testosterone Due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of Heart Attack And Stroke


Chantix (varenicline): Drug Safety Communication - FDA Updates Label to Include Potential Alcohol Interaction


FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni or Sovaldi) in combination with another Direct Acting Antiviral drug


Zyprexa Relprevv (olanzapine pamoate): Drug Safety Communication- FDA Review of Study Sheds Light on Two Deaths Associated with the Injectable Schizophrenia Drug


Nationwide Alert: DEA Calls Opioid a Serious Public Health Threat

12. Adjourn